Compare SCOR & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | SCNX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Other Pharmaceuticals |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 24.8M |
| IPO Year | 2007 | 2020 |
| Metric | SCOR | SCNX |
|---|---|---|
| Price | $6.55 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.2K | ★ 1.8M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $358,940,000.00 | $653,391.00 |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.77 | ★ 207.88 |
| 52 Week Low | $4.39 | $0.46 |
| 52 Week High | $10.18 | $8.19 |
| Indicator | SCOR | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 42.17 |
| Support Level | $6.51 | $0.60 |
| Resistance Level | $7.15 | $0.75 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 67.96 | 8.92 |
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.